Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookie, but we will activate these services only with your consent. If you press the button “Accept”, you consent to the use of these analytics scripts.

You can withdraw your consent at any time. To do so, please modify your configurations on this website by following this link to our privacy statement with the configuration options:
Go to settings

Accept

;

Working towards a world free of pain

Our company has a clear vision of a world free of pain and we maintain a strong focus on this vision in everything we do in our research and development activities.

As a global leader in pain research and development, we are passionate about exploring innovative treatment options that have the potential to meaningfully improve the lives of patients around the world. Every day, Grünenthal’s scientists use their deep expertise to reimagine the future of pain management.

Executing our therapeutic area strategy, we focus on four key areas for creating life-changing innovations: peripheral neuropathic pain, chronic post-surgical pain, chronic lower back pain, and osteoarthritis. We take a holistic approach to pursuing breakthrough treatments for these pain conditions – and explore all possible technologies and modalities. This enables us to pursue our priorities with a solution-agnostic mindset. We focus our in-house capabilities on critical and differentiating areas such as target identification with a strong emphasis on human and clinical validation, translational science as well as disease understanding. While we focus particularly on these critical success factors, we can cover every step in the development of an innovative medicine. At the same time, we are committed to enter into strategic partnerships with innovative players from across industry and academia who share our passion to shape the field and foster the development of meaningful therapies.

“At Grünenthal, we work tirelessly to deliver innovative treatments that make a meaningful difference for patients affected by pain.”

Jan Adams,

Chief Scientific Officer (CSO)

Alongside our focus on these four indications, we’re also seeking to join forces with partners to develop new therapeutic solutions for fibromyalgia, complex regional pain syndrome, migraine and peri-surgical pain.

 

You can find more information about our strategy, global presence, partnerships and projects on this section of our website. And you can also find detailed descriptions of our focus areas below.

Our therapeutic areas